Bionano Genomics Inc (BNGO)
Bionano Genomics, Inc. is a healthcare company focused on genome analysis solutions across the Americas, Europe, the Middle East, Africa, and Asia Pacific. The company develops software for genomics laboratories and provides optical genome mapping systems used to study structural variation and genetic function. Its product lineup includes Saphyr and Stratys instruments, Saphyr Chip consumables, Bionano Prep Kits and DNA labeling kits, the Ionic purification system, and compute servers that support analysis workflows. Bionano also offers VIA software for interpreting genomic data from microarray and sequencing sources. In addition, it provides laboratory testing services such as FirstStepDx PLUS, Fragile X syndrome testing, NextStepDx PLUS, OGM-Dx HemeOne, OGM-Dx FSHD, and postnatal and prenatal whole-genome structural variation tests. The company was founded in 2003 and is headquartered in San Diego, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BNGO
|
$2.16
|
18.7% Upside
|
Undervalued
|
$5
|
174.7% Upside
|
Bargain
|
Good
|
0.0%
|
October 29, 2026
|
0.7x
|
0.7x
|
21.435 M
|
18.22 M
|
23.7%
|
90.3%
|
-22.9
|
63.7%
|
